Arcus Biosciences (RCUS) Revenue (2017 - 2026)

Arcus Biosciences' Revenue history runs 10 years deep, the most recent figure standing at $17.0 million for Q1 2026.

• In Q1 2026, Revenue fell 39.29% year-over-year to $17.0 million; the TTM figure through Mar 2026 stood at $236.0 million (up 67.38% YoY), while the FY2025 annual figure was $247.0 million, down 4.26% from the prior year.
• Revenue for Q1 2026 stood at $17.0 million, down from $33.0 million in the prior quarter.
• The five-year high for Revenue was $160.0 million in Q2 2025, with the low at $14.0 million in Q4 2023.
• The 5-year median for Revenue is $29.0 million (2023), against an average of $43.2 million.
• The sharpest annual moves came in 2022 and 2024: Revenue sank 90.41% in 2022, then soared 480.0% in 2024.
• Arcus Biosciences' Revenue stood at $34.0 million in 2022, then tumbled by 58.82% to $14.0 million in 2023, then jumped by 85.71% to $26.0 million in 2024, then rose by 26.92% to $33.0 million in 2025, then tumbled by 48.48% to $17.0 million in 2026.
• Business Quant data shows RCUS's Revenue at $17.0 million in Q1 2026, $33.0 million in Q4 2025, and $26.0 million in Q3 2025.